BiotechTube

Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapy

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemia Associated With Type II Diabetes Mellitus

Conditions

Dyslipidemia Associated With Type II Diabetes Mellitus

Trial Timeline

Mar 9, 2026 → Dec 31, 2029

NCT ID
NCT07359105

About Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapy

Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapy is a pre-clinical stage product being developed by Yuhan for Dyslipidemia Associated With Type II Diabetes Mellitus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07359105. Target conditions include Dyslipidemia Associated With Type II Diabetes Mellitus.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT07359105Pre-clinicalRecruiting

Competing Products

20 competing products in Dyslipidemia Associated With Type II Diabetes Mellitus

See all competitors
ProductCompanyStageHype Score
LY3202328 + Placebo + Atorvastatin + SimvastatinEli LillyPhase 1
33
Pitavastatin + PravastatinEli LillyApproved
85
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
85
YH14755 + Metformin + RosuvastatinYuhanPhase 3
77
YHR1705 + YHR1706 + YHR1705+YHR1706YuhanPhase 1
33
Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDCYuhanPhase 1
33
MevalotinDaiichi SankyoPre-clinical
23
PravastatinDaiichi SankyoPre-clinical
23
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SCEli LillyPhase 1
33
LY3885125 + PlaceboEli LillyPhase 1
33
LY3561774 + PlaceboEli LillyPhase 1
33
LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for StatinsEli LillyPhase 2
52
LY3561774 + PlaceboEli LillyPhase 2
52
LY2484595 + Placebo + AtorvastatinEli LillyPhase 2
52
EvacetrapibEli LillyPhase 1
33
PPAR alpha + placeboEli LillyPhase 2
52
AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + PlaceboAstraZenecaPhase 1
33
ABT-335 + RosuvastatinAstraZenecaPhase 1
33
AZD6615 + PlaceboAstraZenecaPhase 1
33
AZD0780 + AZD0780 + AZD0780 + Placebo + Placebo + Placebo + RosuvastatinAstraZenecaPhase 1
33

Other Products from Yuhan

generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85